Abstract
Retrospective dala were collected over a 1-year period from the medical records of palicms admitted 10 a district general hospital, either with febrile ncutropenia or who developed this complication whilst receiving inpatient chemotherapy. Costs were calculated for inpatient stay, drug treatment and diagnostic tests. The median total cost for 46 episodes of febrile neutropenia were £2068.35 and the median total costs, per day was £139.41. Inpatient bed-days accounted for 57.8% of total costs, followed by drug treatment at 25.8% and diagnostic tests at 16.4%. The costs of blood products were excluded since they are frequently administered irrespective of the neutropenia. This study serves as a useful pointer to the expenditure in measurable antibiotic costs and investigations in patients with malignant blood disorders who develop febrile neutropenia.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Finch SC. Neutrophil disorders–benign, quantitative abnormalities of neatrophils. In Williams J. editor. Haematology.New York: McGraw Hill Book Co. 1983: 773
Crawford J. Ozer H. Stoller R. et al. Rceuction by grallulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991: 325: 164–70
Pizzo PA. Current issues in the antibiotic primary management of the febrile:neutropenic cancer patient: a prospective from the:National Cancer Institution. J Hosp Infect 1990: 15 Suppl.A:41–8
Gurney H. The problen of neutropenia resulting from cancer therapy. Clinician 1989: 7: 2–10
Hollingshead LM. Goa KL. Recombinant granulocyte colony, stimulating factor: a review of its pharmacological properties and prospectitive role in neutropenia conditions. Drugs 1991:42: 300–30
Faulds D. Lewis N. Milne RJ. Recombinant granulocyte colony-stimulating factor: pharmacoecconomic considerations in chemotherapy-induced neutropenia. Pharmaco Economics 1992: 1: 231–49
Chaplin S. Cancer therapy complication costly ti treat. Hospital Doctor 1991 May 9: 30
Leese B. The costs of treating febrile neutropenia and tile potential savings from G-CSF.In: Chytil MK. Duro G. van Eimeren W. et al editors. Health systems–the challenge of change. Prague: Omnipress Publishers. 1992: 766–8
Leese B. The costs of treating febrile neutropenia in six. UK hospitals. Eur J Cancer 1993: 29A Suppl.1: I5–18
Glaspy JA. Bleecker GC, Stoller RG. et al. Decrcased costs in ca~ncer chemotherapy patients using recombinant granulocyte colony-stimulating factor. Clin Res 1991 39:7
Glaspy JA. Bleecker G. Crawford J. et al. The economic impact of recombinant granulocyte colony-stimulating factor.In:Chytil MK. Duro G, van Eimeren W. et al.editors. Health systems–tile challenge of change. Prague: Omnipress Publishers,1992: 769–71
Glaspy JA. Jakway J. Cost considerations in therapy with my-eloid growth factors. Am J Hosp Pharm 1993: 50 Suppl.3:19–26
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Leese, B., Collin, R. & Clark, D.J. The Costs of Treating Febrile Neutropenia in Patients with Malignant Blood Disorders. Pharmacoeconomics 6, 233–239 (1994). https://doi.org/10.2165/00019053-199406030-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00019053-199406030-00007